van Lingen A - Search Results

1

Calculation of the radiation dose at a bone-to-marrow interface.

van Dieren EB, Plaizier MA, Roos JC, Teule GJ, van Lingen A. van Dieren EB, et al. Among authors: van lingen a. J Nucl Med. 1992 Oct;33(10):1915-6. J Nucl Med. 1992. PMID: 1403167 Free article. No abstract available.

2

Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies.

Plaizier MA, Roos JC, Teule GJ, van Dieren EB, den Hollander W, Haisma HJ, DeJager RL, van Lingen A. Plaizier MA, et al. Among authors: van dieren eb, van lingen a. Eur J Nucl Med. 1994 Mar;21(3):216-22. doi: 10.1007/BF00188669. Eur J Nucl Med. 1994. PMID: 8200389

3

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA. Colnot DR, et al. Among authors: van kamp gj, van dongen ga, van lingen a. J Nucl Med. 2000 Dec;41(12):1999-2010. J Nucl Med. 2000. PMID: 11138685 Free article. Clinical Trial.

4

Kinetics and dosimetry of iodine-131-labelled antibody fragments after local administration in patients with rectal cancer.

Derksen EJ, van Dieren EB, Roos JC, van Lingen A, den Hollander W, Teule GJ, Meijer S. Derksen EJ, et al. Among authors: van dieren eb, van lingen a. Eur J Nucl Med. 1992;19(7):492-6. doi: 10.1007/BF00185854. Eur J Nucl Med. 1992. PMID: 1644105

5

Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.

Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ, Huijgens PC. Hoekstra OS, et al. Among authors: van lingen a. J Nucl Med. 1993 Oct;34(10):1706-10. J Nucl Med. 1993. PMID: 8410287 Free article.

6

Increased uptake of iodine-123-BMIPP in chronic ischemic heart disease: comparison with fluorine-18-FDG SPECT.

Sloof GW, Visser FC, Bax JJ, van Lingen A, Eersels J, Knapp FF Jr, Teule GJ. Sloof GW, et al. Among authors: van lingen a. J Nucl Med. 1998 Feb;39(2):255-60. J Nucl Med. 1998. PMID: 9476931 Free article.

7

Feasibility of planar fluorine-18-FDG imaging after recent myocardial infarction to assess myocardial viability.

Huitink JM, Visser FC, van Lingen A, Groeneveld AB, Bax JJ, van Leeuwen GR, Visser GM, Van Loon MJ, Teule GJ, Visser CA. Huitink JM, et al. Among authors: van leeuwen gr, van loon mj, van lingen a. J Nucl Med. 1995 Jun;36(6):975-81. J Nucl Med. 1995. PMID: 7769455 Free article.

8

Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution.

van Dieren EB, Plaizier MA, van Lingen A, Roos JC, Barendsen GW, Teule GJ. van Dieren EB, et al. Among authors: van lingen a. Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):197-204. doi: 10.1016/s0360-3016(96)00280-5. Int J Radiat Oncol Biol Phys. 1996. PMID: 8823276

9

Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium.

Bax JJ, Visser FC, Blanksma PK, Veening MA, Tan ES, Willemsen TM, van Lingen A, Teule GJ, Vaalburg W, Lie KI, Visser CA. Bax JJ, et al. Among authors: van lingen a. J Nucl Med. 1996 Oct;37(10):1631-6. J Nucl Med. 1996. PMID: 8862297 Free article.

10

Myocardial F-18 fluorodeoxyglucose imaging by SPECT.

Bax JJ, Visser FC, van Lingen A, Visser CA, Teule GJ. Bax JJ, et al. Among authors: van lingen a. Clin Nucl Med. 1995 Jun;20(6):486-90. doi: 10.1097/00003072-199506000-00002. Clin Nucl Med. 1995. PMID: 7648727 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters